HK Stock Market Move | ASCLETIS-B(01672) rose over 4% in the morning, with the core pipeline ASC30 about to start Phase III registration clinical trials.

ASCLETIS-B (01672) rose more than 4% in the morning, as of the time of press release, it has risen by 3.46%, reaching 18.82 Hong Kong dollars, with a turnover of 21.991 million Hong Kong dollars. In terms of news, Gilead Sciences previously announced the initiation of clinical development of ASC30_39FDC and plans to submit an IND application to the US FDA in the third quarter of this year. Soochow pointed out that ASC30 is a GLP-1 small molecule oral/subcutaneous dual dosage form formulation developed by the company. The oral dosage form is expected to submit a Phase III clinical plan to the FDA, with the company planning to officially launch in Q3 2026. According to the current enrollment rate and treatment cycle of weight loss clinical trials, it is expected that the clinical trial will read out data in 2028. It is worth noting that in the report "ASCLETIS-B (01672): Stock price breaking through previous highs is imminent, why are off-market funds choosing to wait and see?", it is pointed out that Gilead's Orforglipron was approved by the FDA for marketing on April 1 this year. The commercial pressure faced by ASC30 and the oral small molecule formulation with Gilead's structure is gradually increasing with the approval of Orforglipron. Although the core advantage of ASC30 lies in factors such as oral convenience, dosing frequency, and patient tolerability, from a commercial perspective, both Gilead's commercial sales capabilities and Orforglipron's market-leading advantages are challenges that Gilead and ASC30 are unlikely to surpass in the short term.